Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study

ERJ Open Research
Shutan LiaoYang Zhang

Abstract

Pulmonary arterial hypertension (PAH) is a common complication of a congenital heart defect (CHD). Recent studies suggest metformin may be a potential drug to improve cardiac function in PAH. A pilot study was conducted to investigate the efficacy of short-term treatment with a combination regimen consisting of bosentan and metformin in PAH-CHD patients as compared with bosentan monotherapy in a prospective, randomised study. Patients with PAH-CHD were randomised to receive bosentan (initially at 62.5 mg twice daily for 4 weeks and then 125 mg twice daily) for 3 months with or without the combination treatment of metformin (500 mg twice daily). 93 patients were enrolled to bosentan monotherapy (n=48) or bosentan/metformin combination treatment (n=45). After 3 months, both treatments significantly improved World Health Organization functional class, 6-min walking distance (6MWD), N-terminal pro-brain natriuretic peptide and right heart haemodynamic parameters. The improvements in 6MWD and pulmonary vascular resistance index were significantly greater in patients treated with combination therapy than in those who received monotherapy (mean±sd 95±136 versus 48±119 m (p=0.017) and -1.8±1.2 versus -1.2±1.3 Wood units per m2 (p<0.001...Continue Reading

References

Mar 15, 1991·Annals of Internal Medicine·D J StewartD Langleben
Feb 15, 1993·The American Journal of Cardiology·P CacoubI Gandjbakhch
Jun 17, 1993·The New England Journal of Medicine·A GiaidD J Stewart
Nov 10, 2001·BMJ : British Medical Journal·A J Vickers, D G Altman
Jul 3, 2002·Annals of Internal Medicine·Dmitri KirpichnikovJames R Sowers
Feb 10, 2004·Metabolism: Clinical and Experimental·Fahim AbbasiGerald M Reaven
Jun 28, 2006·Circulation·Nazzareno GalièUNKNOWN Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators
Mar 19, 2008·Clinical and Experimental Pharmacology & Physiology·Eduardo MeaneyGuillermo Ceballos
Jun 13, 2008·Nature Protocols·Thomas D Schmittgen, Kenneth J Livak
Jul 10, 2013·Diabetologia·Graham RenaKei Sakamoto
Sep 28, 2013·Rheumatology International·Shin-ya KawashiriAtsushi Kawakami
Feb 13, 2014·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Derya KocerHalit Diri
May 9, 2014·Experimental Lung Research·Yuanyuan WuManxiang Li
Sep 27, 2014·Current Opinion in Cell Biology·D Grahame Hardie
Nov 17, 2014·American Journal of Physiology. Lung Cellular and Molecular Physiology·Francis Y KimDavid N Cornfield
Oct 17, 2015·Cardiology Clinics·Eric V KriegerAlexander R Opotowsky
Jun 15, 2016·Hypertension·Afshan DeanMargaret R MacLean

❮ Previous
Next ❯

Citations

Apr 2, 2019·Journal of Cellular Physiology·Chun-Fang ZhangJiao Yang
Feb 14, 2019·American Journal of Respiratory Cell and Molecular Biology·Diederik E van der FeenBeatrijs Bartelds
Feb 6, 2021·Clinics in Chest Medicine·Katherine KearneyEdmund M T Lau
Jun 26, 2021·Frontiers in Cell and Developmental Biology·Qiang ZhaoMing-Hui Zou
Apr 13, 2021·American Journal of Respiratory Cell and Molecular Biology·SeungHye Han, Navdeep S Chandel

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISAs
biopsy
PCR

Software Mentioned

SPSS Statistics

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.